Carmot Therapeutics Inc. (CRMO)

Carmot Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	48.95	48.95	46.81
Short-Term Investments	89.39	89.39	1.22
Cash & Cash Equivalents	138.34	138.34	48.03
Cash Growth	-	188.04%	-
Receivables	0.57	0.57	3.21
Other Current Assets	4.08	4.08	2.01
Total Current Assets	142.99	142.99	53.25
Property, Plant & Equipment	-	2.5	1.6
Long-Term Investments	-	24.41	20.42
Goodwill and Intangibles	-	4.17	-
Other Long-Term Assets	-	0.84	0.5
Total Long-Term Assets	-	31.92	22.52
Total Assets	-	174.91	75.77
Accounts Payable	-	3.95	5.67
Current Debt	-	1.81	30.06
Other Current Liabilities	11.7	5.95	2.56
Total Current Liabilities	11.7	11.7	38.3
Long-Term Debt	-	2.25	-
Other Long-Term Liabilities	-	0	1.7
Total Long-Term Liabilities	-	2.25	1.7
Total Liabilities	-	13.95	40
Total Debt	4.06	4.06	30.06
Debt Growth	-	-86.50%	-
Retained Earnings	-	-65.86	-27.02
Comprehensive Income	-	-0.01	0.05
Shareholders' Equity	-63.71	-63.71	-25.71
Net Cash / Debt	134.29	134.29	17.97
Net Cash / Debt Growth	-	647.36%	-
Working Capital	131.29	131.29	14.96

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).